Journal
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
Volume 14, Issue -, Pages 665-673Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/TCRM.S144481
Keywords
Parkinson's disease; levodopa-induced dyskinesia; amantadine; amantadine-extended-release
Categories
Funding
- Adamas
Ask authors/readers for more resources
Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson's disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri (TM)) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available